// App-Quantinova.ai

P137 : First-line tumour necrosis factor inhibitor (TNFi) treatment is associated with high multi-criteria remission early on compared to treat-to-target in a treatment naïve RA cohort

Researchers

Presenter

  • Rudresh Shukla

Principal Investigators

  • Darren Plant

  • Paul Emery

  • Maya H Buch

Medical Centers

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

  • NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester, United Kingdom

  • NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved